TYK Medicines' (HKG:2410) loss attributable to owners narrowed to 299.8 million yuan for 2025, from 387 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Shares of the pharmaceutical company were up nearly 2% in late morning trade on Tuesday.
Loss per share shrank to 0.80 yuan from 1.15 yuan a year earlier.
The company did not generate revenue in 2025. In 2024, its revenue came in at 107,000 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments